StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

ArriVent BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

ArriVent BioPharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $144.30M, up 11.6% year over year. For fiscal 2025 it was $153.35M, up 94.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$153.35M+94.1%
FY2024Dec 31, 2024$79.00M+21.8%
FY2023Dec 31, 2023$64.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$42.34M+52.7%
Q1 FY2026Mar 31, 2026$37.62M-38.6%
Q4 FY2025Dec 31, 2025$32.18M+59.6%
Q3 FY2025Sep 30, 2025$32.17M+60.1%
Q2 FY2025Jun 30, 2025$27.72M+27.3%
Q1 FY2025Mar 31, 2025$61.29M+261.1%
Q4 FY2024Dec 31, 2024$20.16M+0.8%
Q3 FY2024Sep 30, 2024$20.09M+40.7%
Q2 FY2024Jun 30, 2024$21.78M+7.0%
Q1 FY2024Mar 31, 2024$16.98M+65.8%
Q4 FY2023Dec 31, 2023$20.01M–
Q3 FY2023Sep 30, 2023$14.28M–
Q2 FY2023Jun 30, 2023$20.36M–
Q1 FY2023Mar 31, 2023$10.24M–

More ArriVent BioPharma figures

See a number that looks wrong?